Revvity Beats Analyst Estimates on Earnings and Sales

Buyers of scientific instruments get a read on supplier health as Revvity tops Zacks consensus on adjusted earnings and revenue.

Updated on Nov. 3, 2026 in Economic Indicators

Brushed steel laboratory instrument with clear glass sample cells on a pale bench in a bright, modern lab. — Revvity topped analyst estimates on third-quarter adjusted earnings of $1.38 per share and adjusted revenue of $709.6 million, reported November 3. AI Illustration. Upload story photo >

Waltham, Massachusetts-based Revvity reported third-quarter profit of $62.3 million, or 56 cents per share, on revenue of $728.9 million. Operators in scientific instrument supply chains should note the company beat analyst expectations on both adjusted earnings and revenue.

Why it matters

Revvity's adjusted earnings of $1.38 per share topped the Zacks analyst average estimate of $1.29, and adjusted revenue of $709.6 million beat the $707 million estimate. The results were reported November 3, 2026, and offer a quarter-level read on demand for scientific instruments.

Revvity's adjusted earnings of $1.38 per share beat the $1.29 analyst average, and adjusted revenue of $709.6 million exceeded the $707 million estimate. The company expects full-year earnings of $5.40 to $5.45 per share and revenue of $2.86 billion.

The players

Revvity

Waltham, Massachusetts-based maker of scientific instruments serving life sciences and diagnostics customers.

Zacks

Independent investment research firm whose analyst consensus estimates are widely used as a benchmark for corporate earnings.

The details

Revvity's GAAP profit of 56 cents per share is well below its adjusted earnings of $1.38 per share, a gap that reflects the adjustments the company makes to its reported results. Adjusted figures exclude certain items, so operators comparing supplier performance should look at both measures. The company's reported third-quarter revenue of $728.9 million was higher than its adjusted revenue of $709.6 million, indicating the adjustment runs in the opposite direction on the top line.

November 3, 2026: Revvity reported third-quarter earnings results.

Market Landscape

Revvity's quarter is measured against the Zacks analyst average, the benchmark most investors and operators use to judge whether a company is meeting expectations. Beating that consensus on both earnings and revenue places the company ahead of the expectations set before the report.

Operators who buy scientific instruments or lab equipment should treat Revvity's beat as a signal of supplier financial health rather than a pricing event. Procurement teams should compare the company's GAAP and adjusted figures before drawing conclusions about its stability.

The takeaway

Supplier financial results like Revvity's are useful inputs for vendor reviews, especially when adjusted and GAAP figures diverge. Track the company's full-year guidance of $5.40 to $5.45 per share against future quarterly reports to see whether the outlook holds.